1-20 of 23
Emile E. Voest
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol

Karlijn Verkerk, Tijmen J.W.T. van der Wel, Laurien J. Zeverijn, Birgit S. Geurts, Ilse A.C. Spiekman, Gijs F. de Wit, Paul Roepman, Anne M.L. Jansen, Vincent van der Noort, Egbert F. Smit, Ann Hoeben, Lizza E.L. Hendriks, Michel M. van den Heuvel, Berber Piet, Gerarda J.M. Herder, Sayed M.S. Hashemi, Hans Gelderblom, Henk M.W. Verheul, Emile E. Voest, Adrianus J. de Langen
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (23): 5323–5332.
https://doi.org/10.1158/1078-0432.CCR-24-1925
Published: 02 December 2024
View article titled, Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol
Open the PDF for Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol in another window
Includes: Supplementary data
Journal Articles

The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol

Laurien J. Zeverijn, Birgit S. Geurts, Thomas W. Battaglia, Jade M. van Berge Henegouwen, Gijs F. de Wit, Louisa R. Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Paul Roepman, Wendy W.J. de Leng, Anne M.L. Jansen, Myriam Chalabi, Carla M.L. van Herpen, Lot A. Devriese, Frans L.G. Erdkamp, Mariette Labots, Maja J.A. de Jonge, Emile D. Kerver, Adriaan D. Bins, Lindsay V.M. Leek, Jessica C.L. Notohardjo, Alfonsus J.M. van den Eertwegh, Lodewyk F.A. Wessels, Henk M.W. Verheul, Hans Gelderblom, Joris van de Haar, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (19): 4339–4351.
https://doi.org/10.1158/1078-0432.CCR-24-0480
Published: 01 October 2024
View article titled, The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
Open the PDF for The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol in another window
Includes: Supplementary data
Journal Articles

Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol

Birgit S. Geurts, Laurien J. Zeverijn, Lindsay V.M. Leek, Jade M. van Berge Henegouwen, Louisa R. Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Joris van de Haar, Annemiek van Ommen-Nijhof, Marleen Kok, Paul Roepman, Anne M.L. Jansen, Wendy W.J. de Leng, Maja J.A. de Jonge, Ann Hoeben, Carla M.L. van Herpen, Hans M. Westgeest, Lodewyk F.A. Wessels, Henk M.W. Verheul, Hans Gelderblom, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3735–3746.
https://doi.org/10.1158/1078-0432.CCR-24-0011
Published: 03 September 2024
View article titled, Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Open the PDF for Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol in another window
Includes: Supplementary data
Journal Articles

Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol

Jade M. van Berge Henegouwen, Laurien J. Zeverijn, Birgit S. Geurts, Louisa R. Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Alwin D.R. Huitema, Filip Y.F. de Vos, Katrien Grünberg, Haiko J. Bloemendal, Henk M.W. Verheul, Emile E. Voest, Hans Gelderblom
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3937–3943.
https://doi.org/10.1158/1078-0432.CCR-23-3917
Published: 03 September 2024
View article titled, Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol
Open the PDF for Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol in another window
Includes: Supplementary data
Journal Articles

Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer

Joris van de Haar, Joanne M. Mankor, Karlijn Hummelink, Kim Monkhorst, Egbert F. Smit, Lodewyk F.A. Wessels, Edwin Cuppen, Joachim G.J.V. Aerts, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (7): 1307–1318.
https://doi.org/10.1158/1078-0432.CCR-23-4027
Published: 01 April 2024
View article titled, Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
Open the PDF for Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

Louisa R. Hoes, Jade M. van Berge Henegouwen, Hanneke van der Wijngaart, Laurien J. Zeverijn, Daphne L. van der Velden, Joris van de Haar, Paul Roepman, Wendy J. de Leng, Anne M.L. Jansen, Erik van Werkhoven, Vincent van der Noort, Alwin D.R. Huitema, Eelke H. Gort, Jan Willem B. de Groot, Emile D. Kerver, Derk Jan de Groot, Frans Erdkamp, Laurens V. Beerepoot, Mathijs P. Hendriks, Egbert F. Smit, Winette T.A. van der Graaf, Carla M.L. van Herpen, Mariette Labots, Ann Hoeben, Hans Morreau, Martijn P. Lolkema, Edwin Cuppen, Hans Gelderblom, Henk M.W. Verheul, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1402–1411.
https://doi.org/10.1158/1078-0432.CCR-21-3752
Published: 01 April 2022
View article titled, Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
Open the PDF for Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment in another window
Includes: Supplementary data
Journal Articles

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments

Lennart Kester, Danielle Seinstra, Annelot G.J. van Rossum, Claire Vennin, Marlous Hoogstraat, Daphne van der Velden, Mark Opdam, Erik van Werkhoven, Kerstin Hahn, Iris Nederlof, Ester H. Lips, Ingrid A.M. Mandjes, A. Elise van Leeuwen-Stok, Sander Canisius, Harm van Tinteren, Alex L.T. Imholz, Johanneke E.A. Portielje, Monique E.M.M. Bos, Sandra D. Bakker, Emiel J. Rutgers, Hugo M. Horlings, Jelle Wesseling, Emile E. Voest, Lodewyk F.A. Wessels, Marleen Kok, Hendrika M. Oosterkamp, Alexander van Oudenaarden, Sabine C. Linn, Jacco van Rheenen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 960–971.
https://doi.org/10.1158/1078-0432.CCR-21-1442
Published: 01 March 2022
View article titled, Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments
Open the PDF for Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments in another window
Includes: Supplementary data
Journal Articles

Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types

Hanneke van der Wijngaart, Louisa R. Hoes, J. Maxime van Berge Henegouwen, Daphne L. van der Velden, Laurien J. Zeverijn, Paul Roepman, Erik van Werkhoven, Wendy W.J. de Leng, Anne M.L. Jansen, Niven Mehra, Debbie G.J. Robbrecht, Mariette Labots, Derk Jan A. de Groot, Ann Hoeben, Paul Hamberg, Hans Gelderblom, Emile E. Voest, Henk M.W. Verheul
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (22): 6106–6114.
https://doi.org/10.1158/1078-0432.CCR-21-1104
Published: 15 November 2021
View article titled, Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types
Open the PDF for Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types in another window
Includes: Supplementary data
Journal Articles

Abstract IA19: The Drug Rediscovery Protocol: Getting the most out of approved drugs

Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12_Supplement_1): IA19.
https://doi.org/10.1158/1557-3265.ADVPRECMED20-IA19
Published: 15 June 2020
View article titled, Abstract IA19: The Drug Rediscovery Protocol: Getting the most out of approved drugs
Journal Articles

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

Didier Meulendijks, Wolfgang Jacob, Emile E. Voest, Morten Mau-Sorensen, Maria Martinez-Garcia, Alvaro Taus, Tania Fleitas, Andres Cervantes, Martijn P. Lolkema, Marlies H.G. Langenberg, Maja J. De Jonge, Stefan Sleijfer, Ji-Youn Han, Antonio Calles, Enriqueta Felip, Sang-We Kim, Jan H.M. Schellens, Sabine Wilson, Marlene Thomas, Maurizio Ceppi, Georgina Meneses-Lorente, Ian James, Suzana Vega-Harring, Rajiv Dua, Maitram Nguyen, Lori Steiner, Celine Adessi, Francesca Michielin, Birgit Bossenmaier, Martin Weisser, Ulrik N. Lassen
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5406–5415.
https://doi.org/10.1158/1078-0432.CCR-17-0812
Published: 14 September 2017
View article titled, Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity
Open the PDF for Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity in another window
Includes: Supplementary data
Journal Articles

TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies

Daphne L. van der Velden, Frans L. Opdam, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (12): 2835–2839.
https://doi.org/10.1158/1078-0432.CCR-15-2783
Published: 14 June 2016
View article titled, TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies
Open the PDF for TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies in another window
Journal Articles

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

Didier Meulendijks, Wolfgang Jacob, Maria Martinez-Garcia, Alvaro Taus, Martijn P. Lolkema, Emile E. Voest, Marlies H.G. Langenberg, Tania Fleitas Kanonnikoff, Andres Cervantes, Maja J. De Jonge, Stefan Sleijfer, Morten Mau Soerensen, Marlene Thomas, Maurizio Ceppi, Georgina Meneses-Lorente, Ian James, Celine Adessi, Francesca Michielin, Keelara Abiraj, Birgit Bossenmaier, Jan H.M. Schellens, Martin Weisser, Ulrik N. Lassen
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (4): 877–885.
https://doi.org/10.1158/1078-0432.CCR-15-1683
Published: 14 February 2016
View article titled, First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors
Open the PDF for First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Primary Colorectal Cancers and Their Subsequent Hepatic Metastases Are Genetically Different: Implications for Selection of Patients for Targeted Treatment

Joost S. Vermaat, Isaac J. Nijman, Marco J. Koudijs, Frank L. Gerritse, Stefan J. Scherer, Michal Mokry, Wijnand M. Roessingh, Nico Lansu, Ewart de Bruijn, Richard van Hillegersberg, Paul J. van Diest, Edwin Cuppen, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (3): 688–699.
https://doi.org/10.1158/1078-0432.CCR-11-1965
Published: 31 January 2012
View article titled, Primary Colorectal Cancers and Their Subsequent Hepatic Metastases Are Genetically Different: Implications for Selection of Patients for Targeted Treatment
Open the PDF for Primary Colorectal Cancers and Their Subsequent Hepatic Metastases Are Genetically Different: Implications for Selection of Patients for Targeted Treatment in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors

Stijn L.W. Koolen, Petronella O. Witteveen, Robert S. Jansen, Marlies H.G. Langenberg, Roelien H. Kronemeijer, Annemarie Nol, Ignacio Garcia-Ribas, Sophie Callies, Karim A. Benhadji, Christopher A. Slapak, Jos H. Beijnen, Emile E. Voest, Jan H.M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (18): 6071–6082.
https://doi.org/10.1158/1078-0432.CCR-11-0353
Published: 14 September 2011
View article titled, Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors

Marlies H.G. Langenberg, Petronella O. Witteveen, Jeanine M. Roodhart, Henk M.W. Verheul, Marja Mergui-Roelvink, Jana van der Sar, Erich Brendel, Nicole Laferriere, Jan H.M. Schellens, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (7): 2187–2197.
https://doi.org/10.1158/1078-0432.CCR-09-2436
Published: 31 March 2010
View article titled, Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors
Open the PDF for Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors in another window
Journal Articles

A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies

Bart Kuenen, Petronella O. Witteveen, Rita Ruijter, Giuseppe Giaccone, Aruna Dontabhaktuni, Floyd Fox, Terry Katz, Hagop Youssoufian, Junming Zhu, Eric K. Rowinsky, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (6): 1915–1923.
https://doi.org/10.1158/1078-0432.CCR-09-2425
Published: 14 March 2010
View article titled, A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG<sub>1</sub> Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG<sub>1</sub> Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies in another window
Journal Articles

Clinical and Pharmacologic Study of the Novel Prodrug Delimotecan (MEN 4901/T-0128) in Patients with Solid Tumors

Stephan A. Veltkamp, Els O. Witteveen, Angela Capriati, Attilio Crea, Fabio Animati, Marja Voogel-Fuchs, Ingeborg J.G.M. van den Heuvel, Jos H. Beijnen, Emile E. Voest, Jan H.M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (22): 7535–7544.
https://doi.org/10.1158/1078-0432.CCR-08-0438
Published: 14 November 2008
View article titled, Clinical and Pharmacologic Study of the Novel Prodrug Delimotecan (MEN 4901/T-0128) in Patients with Solid Tumors
Open the PDF for Clinical and Pharmacologic Study of the Novel Prodrug Delimotecan (MEN 4901/T-0128) in Patients with Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Platelets Take Up the Monoclonal Antibody Bevacizumab

Henk M.W. Verheul, Martijn P.J. Lolkema, David Z. Qian, Yvonne H.A. Hilkes, Eleni Liapi, Jan-Willem N. Akkerman, Roberto Pili, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (18): 5341–5347.
https://doi.org/10.1158/1078-0432.CCR-07-0847
Published: 17 September 2007
View article titled, Platelets Take Up the Monoclonal Antibody Bevacizumab
Open the PDF for Platelets Take Up the Monoclonal Antibody Bevacizumab in another window
Journal Articles

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C β-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer

Jeany M. Rademaker-Lakhai, Laurens V. Beerepoot, Niven Mehra, Sandra A. Radema, Rianne van Maanen, Joost S. Vermaat, Els O. Witteveen, Carla M. Visseren-Grul, Luna Musib, Nathan Enas, Gertjan van Hal, Jos H. Beijnen, Jan H.M. Schellens, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (15): 4474–4481.
https://doi.org/10.1158/1078-0432.CCR-06-2912
Published: 01 August 2007
View article titled, Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C β-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer
Open the PDF for Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C β-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer in another window
Journal Articles

A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients

Isa E.L.M. Kuppens, Els O. Witteveen, Roxanne C. Jewell, Sandra A. Radema, Elaine M. Paul, Steve G. Mangum, Jos H. Beijnen, Emile E. Voest, Jan H.M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (11): 3276–3285.
https://doi.org/10.1158/1078-0432.CCR-06-2414
Published: 01 June 2007
View article titled, A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients
Open the PDF for A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients in another window